Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Generic medicines

NHS pays twice the price for generic medicines that manufacturers charge, finds report

A report published by the British Generic Manufacturers Association has shown that the NHS is, on average, paying double what manufacturers charge for Category M products.

Wholesaler stock room ss19


The BGMA-commissioned report finds an “approximate equal division” of profit on generic drugs between wholesalers and pharmacies

The NHS is paying double the initial cost to wholesalers for Category M generic drugs, according to a report commissioned by the British Generic Manufacturers Association (BGMA), the trade body representing generics manufacturers.

The report, written by economics consultancy Oxera and published by the (BGMA) on 26 June 2019, found that drug tariff reimbursement prices for Category M products are, on average, 1.93 times higher than the selling price charged by the manufacturer.

The analysis used actual selling prices for 485 Category M products over 2016 and 2017, and matched the data with tariff prices from the NHS Electronic Drug Tariff Data.

The report said that for around 63% of the products analysed, the reimbursement price was between 40% and 100% higher than the manufacturer’s actual selling price.

“[The analysis] also illustrates, however, that for a sizeable proportion of observations the difference was much larger (up to around 190% higher — i.e. the reimbursement price was 2.9 times the manufacturer selling price in some cases),” the report added.

Avantika Chowdhury, a competition specialist who led the work at Oxera, said that while the findings show that the manufacturers’ selling prices are on average half the price listed on the drug tariff, how the profit “is exactly split will vary, depending on the product”.

But she added that “there’s some analysis, which was done by the BGMA, which shows it’s a 50/50” split, with wholesalers receiving half of the profit and pharmacies receiving the other half.

The report notes that the BGMA compared the “average prices paid by independent pharmacies … and Scheme M actual manufacturer selling prices since 2012” for 50 products to find an “approximate equal division [of the profit] between wholesalers and pharmacies”.

Mike Hewitson, managing director of Beaminster Pharmacy in Dorset, said a price mark-up is “how the wholesaler system operates”.

But he added: “The thing that’s concerning me gravely at the moment is the stability and fairness of that margin that the wholesalers are adding.”

He said that the margins survey, which determines how much of a margin pharmacies have retained through Category M reimbursement, “does require wholesale margins to be fairly static in order for the government to be assured that it’s delivering the right amount of funding to pharmacy”.

“If wholesale margins rise, for example, then money which should be going to pharmacy could be ending up in the pockets of wholesalers,” he explained.

“We’ve got so many examples where prices are jumping two-, three- or four-fold overnight. I’ve seen ten-fold overnight and there’s no explanation for it,” he said.

“There’s a really strong case for more oversight and regulation of wholesale sector in particular.”

The BGMA’s report comes after a report by the National Audit Office found “unexpected increases in wholesalers’ margins” in 2017, “which it could not fully explain”.

The Pharmaceutical Journal has approached the Healthcare Distribution Association, which represents wholesalers, for comment.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2019.20206724

Readers' comments (2)

  • Dear Editor,

    I have to say that I think that this is a particularly unbalanced piece, with the whole tone and drive saying that community pharmacy is making excess profit, until almost the last sentences to put any balance on it.

    There is no comment that this data is from 2016/2017 and there has been a huge shift in the market in the last few years with high clawbacks and Cat M reductions due to 'excess profits'.

    I would appreciate if a bit more thought was placed into making it more balanced as we know that most people will only read about half at best.

    I would appreciate some feedback on my comments.

    Many thanks

    Unsuitable or offensive? Report this comment

  • I'll second that Niall.

    Come on PJ, you should be doing better than this and demonstrate an expert knowledge and understanding of pharmacy.

    That will ensure your content informs those without expert knowledge in a balanced fashion, not like the implications in this article do.

    Unsuitable or offensive? Report this comment

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 1 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £138.50Buy now
  • BNF and BNF for Children

    BNF and BNF for Children

    Now available as a 2 year print subscription to both the BNF and BNFC, ensuring you have the latest medicines information as it publishes and at a greatly reduced price.

    £262.50Buy now
  • Patient Care in Community Practice

    Patient Care in Community Practice

    Patient Care in Community Practice is a unique, practical guide for healthcare professionals or carers. Covers a range of non-medicinal products suitable for use at home.

    £22.00Buy now
  • Pharmaceutical Toxicology

    Pharmaceutical Toxicology

    Explains the methodology and requirements of pre-clinical safety assessments of new medicines. Includes registration requirements and pharmacovigilance.

    £40.00Buy now
  • Strategic Medicines Management

    Strategic Medicines Management

    A practical guide to influencing the availability of medicines, and policies of their use. Focuses on the strategic elements of medicines management.

    £33.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.